Preclinical/clinical studies are developing an immune-mediated therapeutic intervention to also target EpCAM positive cells since high expression of EpCAM (CD326) is one of the most common alterations in solid tumors of epithelial origin, including CRC (NCT03013712) [147,148]. This evidence concerns the gene EPCAM and colorectal carcinoma.